Some blood testing startups focused on early disease are now using liquid biopsy and biomarker testing to validate disease and aid disease prevention.
Theranos is the leader in the field of blood testing to date, and the company's momentum in early 2015 was very strong. However, on October 16, 2015, the Wall Street Journal of the United States questioned Theranos, which spearheaded its technical department. This is followed by federal investigations, sanctions and litigation against Theranos.
We conducted an inventory of some early stage blood testing startups established after the Wall Street Journal released a negative report from Theranos, and also sorted out their financing situation, hoping to show investors some blood testing industry may exist. The opportunity, despite some negative news. Among these blood testing startups, many are working to solve medical problems ranging from lung cancer and colon cancer to Alzheimer's disease. Among them, five medical professional startups are the most prominent, they specialize in different diseases. direction:
Tumor: Grail, Clinical Genomics, CellMax Life, 20/20 GeneSystems, Acuamark Diagnostics, X-Zell;
Neurodegenerative disease: Pre Diagnostics;
Chronic disease: Brainshake;
Pregnancy disease: Metabolomic Diagnostics;
Other: BBB Technologies, Werlabs, InnaMed;
Through the information on the CB Insights website, we have selected these 12 start-up companies in the blood testing industry. These companies have already completed the seed round or conducted the A round of financing, but have not yet conducted the B round of financing. We rank them based on their current total financing. The author has done a detailed finishing for you.
Grail, a company that is developing a cancer detection platform, has introduced a technology that directly measures circulating tumor DNA (ctDNA) in the blood, a process called liquid biopsy. The main technical service provided by Grail is the early detection of cancer in asymptomatic individuals by blood testing. Its current public offerings total $100 million and investors are ARCH Venture Partners, Bezos Expeditions, Bill Gates, Google Ventures, Illumina, Sutter Hill Ventures.
According to Grail, most of the tumor's nucleic acids fall into the bloodstream. Detection of circulating tumor DNA is a direct detection of cancer DNA, rather than an indirect way to detect the effects of cancer. Their goal is cancer and treatment in the early stages, through its ultra-deep sequencing technology to reduce global cancer mortality. In the United States, at least half of all cancers are diagnosed in the third and fourth stages, resulting in lower cancer patient rates, and the detection of cancer at the earliest stage will greatly increase the patient's healing and long-term survival. possibility.
Therefore, in January 2016, Grail was established as a branch of Illumina, a manufacturer of DNA sequencing technology. The goal is to detect all types of early-stage cancer through simple blood tests, and they will provide more accurate detection than mammograms or prostate-specific antigen detection. Grail's technology is called liquid biopsy - tumor-shedding DNA and RNA molecules circulate freely in the bloodstream. After the tumor accounting is isolated from other genetic material in the blood (ultra-deep sequencing), researchers in academia and industry believe that some cancer features can be found in simple blood draws. In addition, liquid biopsy technology has the potential to reduce the number of patients diagnosed with advanced cancer by providing more scalable and less invasive screening methods.
Grail Financing Overview
Raw Pumpkin Kernels,Raw Pumpkin Seed Kernels,Shelled Pumpkin Seeds,Raw Pumpkin Seeds Eaten
Wuyuan county dafeng oil food co.,ltd , https://www.dafengfood.com.cn